EMA/528864/2024

European Medicines Agency decision

P/0395/2024

of 6 December 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bexicaserin (EMEA-003288-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0395/2024

of 6 December 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for bexicaserin (EMEA-003288-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Longboard Pharmaceuticals, Inc. on 29 July 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for bexicaserin, oral solution, oral use, gastroenteral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for bexicaserin, oral solution, oral use, gastroenteral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for bexicaserin, oral solution, oral use, gastroenteral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Longboard Pharmaceuticals, Inc., 4275 Executive Square, Ste 950, 92037 - La Jolla, United States.

EMA/PDCO/333949/2024
Amsterdam, 18 October 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-003288-PIP01-22

Scope of the application

Active substance(s):

Bexicaserin

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of seizures and seizure disorders

Pharmaceutical form(s):

Oral solution

Route(s) of administration:

Oral use

Gastroenteral use

Name/corporate name of the PIP applicant:

Longboard Pharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Longboard Pharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 29 July 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 12 September 2022.

Supplementary information was provided by the applicant on 5 July 2024. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of seizures and seizure disorders

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- oral solution; oral use and gastroenteral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of seizures and seizure disorders

2.1.1. Indication(s) targeted by the PIP

Adjunctive treatment of seizures associated with developmental and epileptic encephalopathies (DEEs) for patients aged one year and older

Adjunctive treatment of seizures in children aged one year and older (and adults) with Dravet Syndrome

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Oral solution

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable
Non-clinical studies	**Study 1 (LP-352-NC-0091)** Definitive juvenile toxicity study in cynomolgus monkeys to support the evaluation of bexicaserin when used in children from 1 year of age. **Study 2 (LP-352-NC-0092)** Definitive juvenile toxicity study in rats to support the evaluation of bexicaserin when used in children from 1 year of age.

Clinical studies	**Study 3 (LP352-201/PACIFIC)** Randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of bexicaserin in the adjunctive treatment of seizures in children from 12 years to less than 18 years of age (and adults) with developmental and epileptic encephalopathies with continued seizure activity. **Study 4 (LP352-202)** Multicentre, open-label, long-term extension study to evaluate safety of bexicaserin in the adjunctive treatment of seizures in adolescents from 12 years to less than 18 years of age (and adults), with developmental and epileptic encephalopathies who completed Study 3. **Study 5 (LP352-301)** Randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of bexicaserin in the adjunctive treatment of seizures in children from 1 year to less than 18 years of age (and adults) with developmental and epileptic encephalopathies with continued seizure activity. **Study 6 (LP352-302)** Randomised, double-blind, placebo-controlled, multicentre study designed to evaluate the efficacy, safety, and tolerability of bexicaserin in the adjunctive treatment of seizures in children 1 year to less than 18 years of age (and adults) with Dravet Syndrome with continued seizure activity. **Study 7 (LP352-303)** Open-label, long-term, study to evaluate the long-term safety and activity of bexicaserin in the adjunctive treatment of seizures in children from 1 year to less than 18 years of age (and adults) with developmental and epileptic encephalopathies with continued seizure activity and have completed either study 5 or 6 (LP352-301 or LP352-302).
Modelling and simulation analyses	**Study 8 (FR-006)** Modelling and simulation population pharmacokinetic study of bexicaserin to support dose selection and exposure-response analysis in children from 2 years to less than 18 years of age (and adults) to evaluate the use of the product in the adjunctive treatment of seizures and seizure disorders in paediatric patients.

	Study 9 Modelling and simulation population pharmacokinetic study to support a dosing strategy for children from 1 to less than 2 years of age in studies LP352-301 (Study 5), LP352-302 (Study 6) and LP352-303 (Study 7); and to confirm or modify the paediatric posology compared to the regimen used in clinical trials.
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.